CDK4 and ovarian cancer: Fascaplysin treatment also reduced the expression levels of cyclin D1, CDK4, Bcl-2 and VEGFA, demonstrating that fascaplysin showed anti-tumor activity on ovarian cancer cell lines by inhibiting CDK4 [43].